Markets

Mass. Movers

Vertex up on hepatitis deals

Vertex’s new headquarters, under construction in South Boston.
David L. Ryan/Globe Staff
Vertex’s new headquarters, under construction in South Boston.

Vertex Pharmaceuticals Inc. said it has entered into deals with GlaxoSmithKline and Janssen Pharmaceuticals to work on potential treatments for hepatitis C. Cambridge-based Vertex already has a hepatitis C drug on the market called Incivek. The separate studies with the British drug company and Janssen, unit of Johnson & Johnson, call for VX-135, another Vertex hepatitis C drug candidate, to be tested in combinations with pills made by those firms. Those studies are scheduled to start early next year.

Advertisement